RXRX — Recursion Pharmaceuticals, Inc.
Is RXRX overbought or oversold? Here is the current MarketMoodz read.
Recursion Pharmaceuticals, Inc. (RXRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $2.90. The rating moved from Neutral to Oversold on November 4, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$2.90
- Last changeMoved from Neutral to Oversold on November 4, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Recursion Pharmaceuticals, Inc. (RXRX) combines an automated biology platform with machine-learning models that can accelerate discovery and create partnership/licensing opportunities, but the business remains dependent on successful translational readouts and external financing. Near-term catalysts include pipeline data and any new collaborations; these can produce sharp moves. Financial health is a key watch item given historical cash burn and the sector-wide tendency toward convertible financings that raise dilution and hedging pressure. Market interest is currently tilted toward large-cap, defensive pharma, which may limit sustained attention for mid-cap discovery names. Outcomes will hinge on clinical readouts, partnership traction, and the company’s ability to preserve runway on acceptable terms.
Key factors
- Proprietary high-throughput biology + machine learning platform that can generate upstream discovery data and potential licensing/commercial opportunities
- Pipeline progress and data-readout cadence are primary near-term value drivers and can create episodic volatility
- Historical cash burn and the need for external financing create ongoing dilution risk and investor sensitivity to liquidity updates
- Broader sector flows favor large-cap pharma and defensive names, reducing risk appetite for mid-cap discovery/AI biotechs
- Recent market tone is cautiously optimistic around earnings and catalysts, which can support short-term trade interest in event-driven biotech names
- Limited publicly available recent filings or social sentiment signals in the provided dataset increase uncertainty about near-term positioning
Risks
- Insufficient cash runway or unfavorable financing terms leading to significant dilution
- Clinical or translational setbacks in lead programs that materially reduce platform credibility
- Competition from large pharmas or other AI-driven discovery platforms that could compress licensing/partnership opportunities
- Execution risk converting platform outputs into durable, revenue-generating partnerships or commercial products
- Regulatory delays or negative readthroughs from related sector approvals/decisions
- Low retail/institutional interest relative to larger, defensive pharma names, limiting downside support
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for RXRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.